Comparative Pharmacology
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
GENOSYL vs NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a cationic detergent antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
Instill 3 to 4 drops into the affected ear(s) 3 to 4 times daily. For otic suspension in adults.
None Documented
None Documented
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Neomycin: 2-3 hours (in adults with normal renal function); may accumulate in renal impairment. Polymyxin B: 6-8 hours (prolonged in renal impairment: up to 36 hours). Hydrocortisone: 1.2-1.5 hours (terminal).
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Neomycin: >90% unchanged in feces after oral administration; negligible renal excretion. Polymyxin B: 60% renal excretion of unchanged drug; remainder nonrenal. Hydrocortisone: primarily hepatic metabolism, <5% renal excretion unchanged.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic